KALA BIO, Inc. — Director's Dealing 2022

Nov 1, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2022-10-31

Reporting Person: Farid Marjan (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-10-31	Stock Option (right to buy)	$6.35	A	1600	Acquired	2032-10-30	Common Stock (1600)	Direct

Footnotes

F1: This option was granted on October 31, 2022 and vests with respect to 1/3rd of the shares underlying the option on October 31, 2023 and as to an additional 1/36th of the shares underlying the option at the end of each successive one-month period thereafter until October 31, 2025.